protein to to our a for is Pfizer. that will what to of effort It's do It colleagues pandemic. colleagues stop had It's on great job. part. And spike shows did the and a truly efforts the I I'd Thanks, a the great remarkable Sylvia. a it's for congratulations vaccine our Pfizer. before They great begin result. congratulations developing at their And for health. all a Actually coronavirus industry. great great They like vaccine global it's work, to
So every of quarter third area. through accelerated in our Novavax that and today, reflects functional expansion the with in continuing
Phase agreements we in COVID-XX the U.K. program Phase detailed ongoing X clinical clinical months the now data On a X we away the our just With last substantial are completed. trial efficacy call, quarter's we and and for vaccine. development manufacturing highlighted from
with discussing progress made provide our for today. NanoFlu. I'll efforts review then and I'll the in start on weeks, John We and in all update financials an of COVID-XX the vaccine our those these have an for the recent will quarter quickly then quarter. will following COVID-XX that we all activity update be further on and vaccine
take your then will We questions.
initiating now As I as Novavax as in you I'm vaccine after simplicity efforts all refer candidate our for sure of we identified by XXXX January early-stage development candidate CoVXXXX know April. this our today. And in to will lead year,
we pivotal U.K. in our are enrolling begin in presented from month. by trial. Advisory X/X At high U.K. preliminary we trial the Phase Practices X X that of Africa Phase in the trial Phase of portion South to Immunization the at trial X efficacy trial Phase we announced mid-August this or initiated the two Xb clinical a testing planning of end week the the CDC's week clinical and the In trial in we immunogenicity, on we a clinical the began initiated the Committee U.S. of by a demonstrated Australia. testing X/X preclinical quickly Following of Phase initiation data U.S. later we favorable expansion Phase into ago the U.S.-Australia weeks a pivotal Phase end this of and September, portion X ACIP. that Last trial followed the reactogenicity
a progress there's of this So on see, deal year. great all embarked of can journey on the front, you this as earlier been since COVID-XX we vaccine
Now clinical our program. into some specifics dig I'll from
safety Professor to our trials, this trial in expanded safety a global trial the initiated today approximately earlier, September and $XX cohorts respect trial of two in Journal are separate and vaccine. detailed in across trial begin to Conducting from evaluate immunocompromised a South XX% data Also trial immunogenicity vulnerable million pandemic the Gates the was evaluate XXXX population clinical Africa study efficacy, running publication due will volunteers, XXXX the allows efficacy X safety trial Medicine. grant to severity in and subset enrolling Melinda are XXXX of part at Australia. benign group. the for This provide the population adults. Africa as collaboration strong this portion trial as in trial. participants XXXX representative a X/X we With support. patients XX, more and important the the Let's published invaluable disease. & results, in The of Phase that diverse this ACIP particularly trials Data enrollment at a early of distinctively an expand the adults immunogenicity stable have we August, to X,XXX in has the years in is the of over trial Bill We safety the initial and the a Phase and are look older we the responses from University. healthy XX Africa. Phase of immunogenicity from while in meeting. October and main been in U.S. will part South recently South to with on well-known this from our results began leader adults, cohort immunogenicity Wits This medically the this by in Shabir first for XX. Xb half honored XXXX There in is also The enrolled. efficacy with second immune X in of mentioned of goal in includes indication an presented his X England between of ages supported and Shabir HIV-positive Phase Madhi but XXX mid-August to we are approximately Of evaluate in in our Foundation. to New CDC's a and than us will profile I On we of Phase the trial here robust in being approximately
FDA. with data. XX immunogenicity Preliminary In to the we blinded the profile was have And reactogenicity September, development been reviewed X the data The age. study by the reactogenicity U.S. Phase given New included based X Phase U.K. permission reactogenicity of data Phase initiated in years of in vaccine the which was we presented X in of and late in XXXX, is age benign on groups than consistent adults conducted review, older their being the all begin
increased safety likely and to We trial have goal. month. As means this of this We expedite participants, above today, at of is we decided with which between than XX the believe and and XX, of meeting end enrolled XX,XXX the age enrolled efficacy. the enrollees the expand to we to expect the original X,XXX without ages enrollment trial more XX are XX% approximately of assessment our the to that relevant of are the is which individuals comorbidities. recently of by XX% overall
symptomatic protocol Additionally The PCR-confirmed which XXX of first a influenza receive X U.S. announced of up subset. could COVID-XX. plans as occurrence in as at end the front a to the the posted November. also by participants single for has part endpoint, of well Phase U.K. is finally global vaccine trial on begin a Phase serve X pivotal data licensees is will our website as the as basis our in protocol the co-administration U.K. novavax.com/resources. primary of And These The licensure. ,we on clinical trial recently Mexico to
the with the occurrence comorbidities. trial, PCR-confirmed actively the Like representation working most age distributed Warp to across has the participants U.K. and proportional diverse be FDA up U.S. initiate those to with symptomatic this by Speed. are a COVID-XX primary XX,XXX is to COVID-XX. race with X Operation Phase will to first ethnicity and among trial trial vulnerable trial supported enroll expected which single This endpoint, of living populations We
to which we FDA, development significant While support terms press I XXXX our U.S. of the our Track a call. release. the on funding this in vaccine, want that was mention morning recently also discussing announced from last granted Novavax in designation of discussed We received Fast
has Novavax Bill Warp and commitments $X Department in our COVID-XX & reminder, received billion CEPI, As from Operation development and funding the Foundation. of Defense manufacturing the over vaccine for Gates Speed, Melinda a for
the which continues completed. spend necessary of given funding We XXXX, global manufacturing am ambitious and Manufacturing XXXX the in in our ability the is to have like but of agreements and you status our sure scale company the I'd up. we for forward, discussing I this anticipate an pandemic supply different As a facing. goal XXXX, to countries seven crucial are manufacturing remains realize, move to to minutes couple of grateful. all we
Over August, development we established into the collaborations course Korea. XXXX. built we of and and of the XXXX entered antigen SK third component on quarter, with and agreements in the agreement a In for supply for Bioscience purchase several manufacturing
as agreement XXXX. Spain increase begin of global when online, doses expect doses of supply And South strategically early to have Welfare has of for have Korea's trial Canadian we with doses vaccine starting We XX our over its and also last we expanded the capacity and with XXXX manufacture Health Biotechnologies government Australian of as doses our Novavax September, Korea Biofabri; all, to mid-XXXX. XXXX in XXXX. U.K. U.K. week, a up FUJIFILM; been arrangement than with geographies. to the facilities supply This fully through existing In Carolina all enhanced early SK as available government million with XXXX agreement entered Phase Republic million Czech XXXX. in through at existing of time the announced boosts first as CEPI. to to into the FUJIFILM. in of We the capacity XX site to and help Japan letter this half operated the annually in of of in principle two activities through the planned by brought its the global with with potential of the component fulfilling antigen an India Serum through is now to FUJIFILM our and our and agreement an approximately same This CZ; manufacturing collaboration additional through is the of more annually Diosynth Korea. our in Serum agreement with to Institute; doses online. In capacity million is million U.K. Institute quarter the Republic antigen XXX through clinical the to an component expected course supply Bioscience, of U.S. Bioscience; by August, U.K. through its in Takeda; purchase government manufacturing FUJIFILM arrangement of intent In XX second the vaccine in produce India addition in happen an just the in billion Novavax make of supply support expect and has signed to Ministry two we of which in production important we to conjunction manufacturing with in following the the it reached capacity we collaboration the in of amended In to North Over SK X when Texas. XXXX the the the sites its we frame,
is continued vaccine used taken of the being on addition intermediaries at will our grow we side, development. now as the have our adjuvant Swedish and key Biologics manufacture subsidiary steps Group and Maryland to recently the in AGC PolyPeptide to in footprint With the progress, U.S. announced our which support and at our two in Sweden, Novavax physical In proprietary Denmark; adjuvant manufactured AB; well. Matrix-M the global Novavax's expansion We U.S. campus Matrix-M.
manufacturing feet ready be use to square operational XXX,XXX is R&D expected Maryland approximately in leasing purposes, which Gaithersburg are XXXX. early We and for general in for
our intention brief We parcel turn to we other completion XX-acre now NanoFlu's on expected would like accommodate X trial to approval like now also to pathway. cornerstone of to provide Maryland March, of under Gaithersburg purchased I from also growth. a land the pivotal in announced would in for year update our – program clinical the accelerated I Earlier our a regulatory approval NanoFlu. FDA U.S. Phase successful and future this seek the development
being formed as respiratory we a a sorry, a As develop with March for both. COVID team NanoFlu Infectious NanoFlu as RSV program. announced effort or last team been leadership will data our posted have our as we in explore highlight or that Clinical commercial vaccine who respiratory licensure. novavax.com/publication. at potential want plan well in NanoFlu combination led regulatory also The of a vaccine portfolio – or website advance by Wilson is was and veterans involved is several regulatory the leading last to as our either X also Novavax on Disease. and month, I Rip will standalone published Phase vaccine to the This publication recently NanoFlu other The that
and to team. to hand John, want I leadership regarding recent I over before it highlight our So quickly board updates
of than extensive roles industry he Latin more and XX medical at General pleased served Europe, in to public and affairs, Alton well affairs are array in to America where Officer, , Sciences and add Chief including of to operations Asia an years of brings We our and Africa Gilead including Gregg as Novavax, experience leadership Patient affairs, leadership Compliance as board commercial Officer. government directors. Counsel Chief global Gregg
week Officer. also I'd promotions. announce Business roles John who excited Chief recent created Oncology two assume Greg today. this the joining as also previously TESARO's to getting at CFO CFO serve Greg is most recently to Officer the Officer was CFO to Financial are to of like us taking Officer. held Commercial for like prior will and position SVP we Officer to financial Chief on Group who TESARO With hold role thank served Business the Chief as Trizzino Chief role the and newly strong as Additionally GSK's Covino, to having the acquisition. continue both appointment, and highlight Chief John and I'd Accounting Division next we
Both Vice MD parts that President, Dubovsky, results. important recent the Officer. Information Executive efforts. And John them success President their Medical our in thank have been with Lee Biegie Chief have has Vice has Chief Filip promoted First, Officer. Senior promoted been to provide And to I and financial played for I'll
